最新发布

🎥 Inside Faraday Earth’s bid to make cheap green ammonia without Haber-Bosch

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Faraday Earth] Can a container-sized plasma reactor…

盐城利民子公司拟建1200吨氟唑菌酰胺、800吨氟唑菌酰羟胺等农药改造项目

世界农化网中文网报道:近日,关于黄龙生物科技(辽宁)有限公司1500吨二氟吡唑酸综合利用及VOC治理改造项目在相关网站公示。

The hidden innovation system behind drug repurposing 

Pharmaceutical innovation often follows a familiar model: companies invest heavily in drug development, patents protect the resulting products, and commercial returns help fund the next generation of medicines. 

Boehringer licenses PVT virus platform for cancer vaccines

Why it matters: The deal gives Boehringer access to a viral vector technology that could support off-the-shelf cancer vaccines, a different route from the personalised mRNA approaches that dominate much of today’s therapeutic cancer vaccine discussion.

🎥 Can non thermal plasma seed treatment move from lab curiosity to broadacre reality?

[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Sylvarum] Using non-thermal plasma or high voltage …

New Tetra Pak Bioreactor Promises Lower Costs From Pilot to Full-Scale Fermentation

Tetra Pak has launched its first industrial bioreactor, the Tetra Pak® Bioreactor RF, seven months after acquiring Bioreactors.net, the Latvia-based fermentation equipment specialist. The vessel is designed for producers moving fermentation-derived ingredients from pilot testing into full industrial output, and is available in sizes ranging from 10 to 50,000 litres, according to the company.

Graph Therapeutics raises $5m to advance I&I pipeline

Why it matters: Graph is moving from platform development into proprietary drug discovery, a shift many TechBio companies are pursuing as they try to capture more value from AI-enabled biology.

欧盟批准科迪华三事件堆叠转基因玉米及其子组合产品投放市场

大农化网报道:2026年7月3日,欧盟委员会正式发布实施条例(EU)2026/1443,批准由转基因玉米DP202216 × NK603 × DAS-40278-9及其子组合(DP202216 × NK603、DP202216 × DAS-…

Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout

Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals for $10 billion cash, the companies said, in a deal that would expand the buyer’s rare disease portfolio beyond its anchor indication of cystic fibrosis (CF), by adding an approved treatment and a pipeline anchored by two Phase III candidates, all predicted to generate more than $5 billion in annual revenue.

Thailand Eyes Carbon-Fed Microbial Protein as New Export Frontier

Thailand’s Ministry of Commerce is exploring carbon capture and utilisation (CCU) technology as a route into the global alternative protein market, according to a report from The Nation Thailand. The ministry’s Trade Policy and Strategy Office (TPSO) has flagged what it calls “carbon protein” as a frontier industry that could serve both food security goals and the country’s decarbonisation targets.